Composition : Ribociclib
Strength availability : 200mg
Pack : Blister pack contains 21 tablets
for MORE INFORMATION !!!
Kisqali 200mg is an anti-cancer ("antineoplastic") chemotherapy drug. This medication is classified as a "cyclin-dependent kinase inhibitor."4 and 6 (CDK4/6).
Kisqali 200mg is a targeted (biological) therapy. This group of drugs block the growth and spread of cancer. They target and interfere with processes in the cells that cause cancer to grow.
Kisqali 200mg is indicated in combination with letrozole which an aromatase inhibitor for the treatment for women with breast cancer
peak plasma concentration is 1-4 hr and steady state achieved is 8 days
Human serum protein bound is 70%
primarily metabolised by hepatic through CYP3A4 in humans
Kisqali is excreted through feces 69% and urine 23%
Half -life is 32.6 hours.
The usual dose of Kisqali is 600mg (three 200mg film coated tablets) administrated orally once daily for 21 consecutive days followed by 7 days off therapy resulting in a complete cycle of 28 days
The drug Kisqali can be administrated with or without food.
overdose with Kisqali in human has experienced very limited. In case occurs provide general symptomatic and supportive measures.
Some proteins in the body results in cells to develop and divide. In ER positive (ER+), HER2 negative breast cancer, these proteins can turn into overactive and provoke breast cancer cells to develop. Ribociclib works by stopping these proteins, helping to inhibits the cancer cells growing and dividing.
When concomitant use with hormone treatmentwhichstops the effects of oestrogen on cancer cells, Ribociclibsupport to delay the growth of ER+, HER2 negative breast cancer.
Kisqali has been exposed to prolong the QT interval in a concentration-dependent manner. Based on the observed QT prolongation during therapy, Kisqali may needed dose interruption, reduction, or discontinuation.
Avoid the combination use with tamoxifen due to increased QT prolongation.
In patients with advanced or metastatic breast cancer will increases in transaminases were resulted; perform liver function test before starting treatment with Kisqali; based on severity of the transaminase elevations, Kisqali may require dose interference, reduction or stopping.
Interaction of Kisqali 200mg with strong CYP3A4 inhibitor will increased Ribociclib exposure in healthy subjects but this combination cannot be avoided, so reduce the dose of Kisqali to 400mg once daily Kisqali 200mg concomitant use with strong CYP3A4 inducers will decreased Ribociclib exposure in healthy subjects by 89% Co administration of midazolam with multiple doses of Kisqali will increased the midazolam exposure by 3.8-fold in healthy subjects.
If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. Consult doctors regarding missed dose.
The drug Kisqali is store at 20℃ to 25℃
• Decreased in blood counts
• Nausea and vomiting
• Increased liver enzymes
• Hair loss
• Decreased kidney function
• Lack of appetite
• Urinary tract infection.